Autologous unpurged bone marrow transplantation for acute non-lymphoblastic leukaemia in first complete remission.
Twenty-five patients with acute non-lymphoblastic leukemia (ANLL) in first complete remission underwent autologous bone marrow transplantation (ABMT) between March 1984 and March 1988. The high-dose therapy employed included cyclophosphamide followed by total body irradiation (10 Gy), administered as a single dose. The median time from complete remission to ABMT was 5 months (range 2-9 months). Thirteen (52%) patients remain in complete remission 10-51 months (median 25 months) after ABMT and 14-60 months (median 32 months) after achieving complete remission. Causes of death were recurrent leukemia (five patients), parenchymal toxicities (acute respiratory distress syndrome, veno-occlusive disease) (three patients), cerebral haemorrhage (one patient), cerebral aspergillosis (one patient) and viral hepatitis (one patient). Six patients relapsed at a median of 5 months after ABMT (range 4-10 months). In conclusion, this study has resulted in survival data comparable to those of other institutions and the best reported outcomes of conventional chemotherapy.
Carella
A M
AM
Division of Haematology, Ospedale S. Martino, Genoa, Italy.
Gaozza
E
E
Santini
G
G
Martinengo
M
M
Pungolino
E
E
Piatti
G
G
Congiu
A
A
Nati
S
S
Carlier
P
P
Giordano
D
D
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D014182:Transplantation, Autologous; D014916:Whole-Body Irradiation
D003520:Cyclophosphamide